Cells (Jun 2020)

Progressively De-Differentiated Pancreatic Cancer Cells Shift from Glycolysis to Oxidative Metabolism and Gain a Quiescent Stem State

  • Giulia Ambrosini,
  • Elisa Dalla Pozza,
  • Giuseppina Fanelli,
  • Claudia Di Carlo,
  • Andrea Vettori,
  • Giuseppe Cannino,
  • Chiara Cavallini,
  • Cristian Andres Carmona-Carmona,
  • Jessica Brandi,
  • Sara Rinalducci,
  • Maria Teresa Scupoli,
  • Andrea Rasola,
  • Daniela Cecconi,
  • Marta Palmieri,
  • Ilaria Dando

DOI
https://doi.org/10.3390/cells9071572
Journal volume & issue
Vol. 9, no. 7
p. 1572

Abstract

Read online

Pancreatic ductal adenocarcinoma (PDAC) is typically characterized by high chemoresistance and metastatic spread, features mainly attributable to cancer stem cells (CSCs). It is of central interest the characterization of CSCs and, in particular, the study of their metabolic features in order to selectively identify their peculiarities for an efficient therapeutic approach. In this study, CSCs have been obtained by culturing different PDAC cell lines with a specific growth medium. Cells were characterized for the typical stem/mesenchymal properties at short-, medium-, and long-term culture. Metabolomics, proteomics, analysis of oxygen consumption rate in live cells, and the effect of the inhibition of lactate transporter on cell proliferation have been performed to delineate the metabolism of CSCs. We show that gradually de-differentiated pancreatic cancer cells progressively increase the expression of both stem and epithelial-to-mesenchymal transition markers, shift their metabolism from a glycolytic to an oxidative one, and lastly gain a quiescent state. These quiescent stem cells are characterized by high chemo-resistance, clonogenic ability, and metastatic potential. Re-differentiation reverts these features, re-activating their proliferative capacity and glycolytic metabolism, which generally correlates with high aggressiveness. These observations add an important piece of knowledge to the comprehension of the biology of CSCs, whose metabolic plasticity could be exploited for the generation of promising and selective therapeutic approaches for PDAC patients.

Keywords